Effectiveness of a COVID-19 Booster Vaccine to Prevent Re-infection and Study of Antibody Changes in Lung Cancer Patients Receiving Systemic Anti-cancer Treatment

What this Trial Is About

Researchers are evaluating the effectiveness of a single COVID-19 booster dose in lung cancer patients undergoing systemic anti-cancer treatments. This study compares rates of repeated COVID-19 infection, severe lung inflammation, and death between patients who receive a booster mostly targeting XBB variant and those who choose not to get vaccinated. Additionally, the study monitors specific antibody levels in the blood to understand their relationship with breakthrough infections and to find the best timing for vaccination. Participants who choose vaccination will receive one booster dose about six months after their latest symptomatic COVID-19 infection. Both vaccinated and non-vaccinated groups will be observed for six months to track any repeated infections, severe COVID-19 cases, and mortality. Blood samples will be taken at 3, 4.5, and 6 months after the last infection and after vaccination to analyze antibody changes. During the study, participants will have regular check-ups to record health events and provide blood samples for antibody testing. Researchers will measure how often reinfections and severe COVID-19 occur, overall survival, and adverse events related to cancer treatments or vaccination. The total follow-up period for each participant after vaccination or non-vaccination is six months, with additional safety and survival monitoring up to eight weeks after the booster dose.

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research